Annotation Detail
Information
- Associated Genes
- ABL1
- Associated Variants
- ABL1 ABL1-RCSD1
- Associated Disease
- Pediatric B-lymphoblastic Leukemia
- Source Database
- CIViC Evidence
- Description
- This case report describes a patient with relapsed B-ALL positive for the RCSD1-ABL1 fusion, who was successfully treated with chemotherapy with addition of imatinib; the patient remained disease free for 36 months. This case supports sensitivity of B-ALL with RCSD1-ABL1 fusions to ABL-type tyrosine kinase inhibitors.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/7783
- Gene URL
- https://civic.genome.wustl.edu/links/genes/4
- Variant URL
- https://civic.genome.wustl.edu/links/variants/2681
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Pediatric B-lymphoblastic Leukemia
- Evidence Direction
- Supports
- Drug
- Imatinib
- Evidence Level
- C
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 27125982
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Imatinib | Sensitivity | true |